In various clinical and experimental contexts, higher GH levels correlate with increased fat breakdown and favorable changes in lean mass, making GH-releasing peptides of interest in metabolic research
For example, semaglutide lowered kidney complications in people with type 2 diabetes and chronic kidney disease in a trial of more than 3,500 patients, and the FDA approved Ozempic for chronic kidney disease in people with type 2 diabetes in January 2025
These include neurodegenerative disorders, liver diseases, and inflammatory conditions because of their ability to scavenge free radicals and reduce oxidative damage
Persistence of newer anti-obesity medications in a real-world setting
GI side effects, anesthesia risk with GLP-1 agonists: what to know
Zero published outcomes data from over 1 million annual prescriptions is the most significant gap